Polgár, Tímea and Keserű, György Miklós (2014) Structure-Based beta-Secretase (BACE1) Inhibitors. CURRENT PHARMACEUTICAL DESIGN, 20 (20). pp. 3373-3379. ISSN 1381-6128
|
Text
Curr Pharm Design.pdf Download (547kB) | Preview |
Abstract
Alois Alzheimer identified first abnormal deformation in the brain of diseased people with mental disorder. The disorder is clinically characterized by a progression from episodic memory problems to a slow global decline of cognitive function, ending with the final stage when patients become bedridden and death occurs on average 9 years after diagnosis. The current standard of care does not cover the approved and effective treatment of both cognitive and non-cognitive symptoms. Tremendous effort was put in investigation of the disease development. The uncovered molecular mechanism shed light on aspartic proteases, the smallest protease class with about 15 members in the human genome. Here we summarise the most important structure-based developments on one of the most popular aspartic protease target BACE1.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PART 1; ACTIVE-SITES; ENSEMBLE-DOCKING; PEPTIDOMIMETIC INHIBITORS; LEAD GENERATION; PROTONATION STATES; DRUG DISCOVERY; ALZHEIMERS-DISEASE; HYDROXY ETHYLAMINES HEAS; X-RAY CRYSTALLOGRAPHY; Virtual screening; Structure-Based Drug Design; BACE1; Alzheimer disease |
| Subjects: | R Medicine / orvostudomány > RM Therapeutics. Pharmacology / terápia, gyógyszertan |
| SWORD Depositor: | MTMT SWORD |
| Depositing User: | MTMT SWORD |
| Date Deposited: | 11 Nov 2014 09:11 |
| Last Modified: | 01 Oct 2015 23:15 |
| URI: | http://real.mtak.hu/id/eprint/18313 |
Actions (login required)
 |
Edit Item |
